Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01823835 · ClinicalTrials.gov registry record · Phase 1
A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Phase 1 study, sponsored by Genentech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 152
- Enrollment target
NCT01823835 is a Phase 1 study that was terminated before completion, run by Genentech. The registered enrollment target is 152 participants.
The verdict
NCT01823835, a Phase 1 study, was terminated before completion, sponsored by Genentech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 152 participants
- Enrollment target
Study Summary
This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of-concept study of GDC-0810 as a single agent and in combination with palbociclib and/or LHRH agonist. The study is divided into 3 phases: Phase Ia, Phase Ib, and Phase IIa. During Phase Ia (dose escalation phase), GDC-0810 single agent will be administered orally on a continuous daily dosing regimen with a Day -7 lead-in period for single dose PK evaluation prior to the start of daily treatment. The incidence of dose-limiting toxicities (DLTs) will be evaluated from Day -7 through the first cycle (28 days) of treatment (35 days total). Depending on safety and tolerability, participants will be assigned sequentially to escalating doses of GDC-0810 using standard 3 + 3 design. During Phase Ib (dose escalation and expansion phase), participants will receive GDC-0810 with palbociclib and/or LHRH agonist to determine the recommended Phase II dose (RP2D) and assess the safety and tolerability of concomitant administration. During Phase IIa (dose expansion phase), participants previously treated with an aromatase inhibitor (AI) will be treated at the RP2D to further characterize the safety, PK, pharmacodynamics, and anti-tumor activity of GDC-0810.
Interventions
- DRUG Palbociclib
- DRUG LHRH Agonist
- DRUG GDC-0810
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2014-12-29 |
| Est. Completion | 2020-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01823835
The ClinicalTrials.gov registry entry for NCT01823835 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Palbociclib is the first listed.
NCT01823835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01823835 about?
NCT01823835 is a clinical study titled "A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer". This study is a multi-institution, Phase Ia/Ib/IIa open-label, dose-finding, safety, pharmacokinetics (PK), and proof-of-concept study of GDC-0810 as a single agent and in combination with palbociclib and/or LHRH agonist. The study is divided into 3 phases: Phase Ia, Phase Ib, and Phase IIa. During ...
What is the current status of trial NCT01823835?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 152 participants. The study started on 2014-12-29. Estimated completion is 2020-03-13.
What interventions are being tested in trial NCT01823835?
The interventions under investigation include: Palbociclib (DRUG), LHRH Agonist (DRUG), GDC-0810 (DRUG).
Who is sponsoring clinical trial NCT01823835?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.